We read with interest the article by Roussel et al1 evaluating the use of metformin in patients with diabetes and atherothrombosis. The potential role of metformin in reducing all-cause mortality was first published in 1998.2 Since then, numerous additional observational studies have supported mortality reduction with the use of metformin therapy.3
Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Levels of Evidence Needed for Changing Indications, Contraindications, and Food and Drug Administration Labeling: The Case of Metformin. Arch Intern Med. 2011;171(11):1042–1043. doi:10.1001/archinternmed.2011.224
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: